Giant cell tumors of the sacrum--a nationwide study on midterm results in 26 patients after intralesional excision

L. van der Heijden, M.A.J. van de Sande, I. C.M. van der Geest, H. W.B. Schreuder, Barend J. Van Royen, P.C. Jutte, Jos A M Bramer, F. C. Öner, A.P. van Noort-Suijdendorp, H.M. Kroon, P D S Sander Dijkstra

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)

Abstract

PURPOSE: Evaluation of recurrences, complications and function at mid-term follow-up after curettage for sacral giant cell tumor (GCT).

METHODS: We retrospectively studied all 26 patients treated for sacral GCT in the Netherlands (from 1990 to 2010). Median follow-up was 98 (6-229) months. All patients underwent intralesional excision, 21 with local adjuvants, 5 radiotherapy, 3 IFN-α, 1 bisphosphonates. Functional outcome was assessed using Musculoskeletal Tumor Society (MSTS) score. Statistics were performed with Kaplan-Meier, Cox regression, log rank and Mann-Whitney U.

RESULTS: Recurrence rate was 14/26 after median 13 (3-139) months and was highest after isolated curettage (4/5). Soft tissue masses >10 cm increased recurrence risk (HR = 3.3, 95 % CI = 0.81-13, p = 0.09). Complications were reported in 12/26 patients. MSTS was superior in patients without complications (27 vs. 21; p = 0.024).

CONCLUSION: Recurrence rate for sacral GCT was highest after isolated curettage, indicating that (local) adjuvant treatment is desired to obtain immediate local control. Complications were common and impaired function.

Original languageEnglish
Pages (from-to)1949-1962
Number of pages14
JournalEuropean Spine Journal
Volume23
Issue number9
DOIs
Publication statusPublished - 1 Sept 2014

Fingerprint

Dive into the research topics of 'Giant cell tumors of the sacrum--a nationwide study on midterm results in 26 patients after intralesional excision'. Together they form a unique fingerprint.

Cite this